scispace - formally typeset
S

Sondre Heimark

Researcher at University of Oslo

Publications -  16
Citations -  120

Sondre Heimark is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Medicine. The author has an hindex of 4, co-authored 7 publications receiving 87 citations.

Papers
More filters
Journal ArticleDOI

Adherence to medication and drug monitoring in apparent treatment-resistant hypertension

TL;DR: Therapeutic drug monitoring and directly observed therapy with subsequent ambulatory blood pressure measurement are considered to be reliable methods and should be used more in the routine assessment of patients with apparent treatment-resistant hypertension.
Journal ArticleDOI

Tertiary work-up of apparent treatment-resistant hypertension.

TL;DR: The prevalence of true TRH is assessed in a population of patients with apparent TRH in a university hospital setting of tertiary work-up and also investigate reasons for poor BP control and evaluate how work- up can be performed in general practice and secondary care.
Journal ArticleDOI

A Case for Less Intensive Blood Pressure Control: It Matters to Achieve Target Blood Pressure Early and Sustained Below 140/90 mmHg

TL;DR: Assessment of large, randomized, and controlled trials on BP targets, as well as selected observational analyses from other large randomized BP trials, indicate the best preventive effect when achieving early and sustained BP control rather than low targets.
Journal ArticleDOI

Apparent treatment-resistant hypertension - patient-physician relationship and ethical issues.

TL;DR: It is believed that physicians should reflect and discuss potential challenges of drug adherence, and that patient education, information and a solid patient–physician relationship are essential for achieving drug adherence.
Journal ArticleDOI

Which Target Blood Pressure in Year 2018? Evidence from Recent Clinical Trials

TL;DR: These studies confirm a positive effect on cardiovascular protection with blood pressure lowering treatment to between 120–140 mmHg in patients with and without diabetes, but no additional effect of lowering blood pressure to < 120mmHg; possibly too aggressive treatment may increase both cardiovascular morbidity and mortality.